Group treks Great Wall of China to raise £85k
A group of people who trekked along the Great Wall of China have raised more than £85,000 in support of a hospice.
The team took on the challenge to fundraise for Dove House Hospice, which is a charity that provides respite and end-of-life care for people in Hull and East Yorkshire.
The hospice warned they were facing a funding shortfall in April due to rising costs.
Singer Ruth Scott, from Hull, said she took part in the walk because the charity provided "incredible care" for vulnerable people and their families.
Dove House costs about £11m a year to run, but the charity only receives about £1m in statutory funding. The rest of its funds are raised by the community.
Twenty people signed up for the site's latest fundraising challenge and set off for China 17 May, walking a 31-mile (50km) route along the Great Wall.
Upon her return, Ms Scott said: "It's not an easy walk, incredibly steep in places, a lot of the wall is rubble.
"The views are just unbelievable. You can't comprehend.
"It's a privilege if I'm honest, to be able to go there."
She said she had felt inspired by the charity's work throughout the challenge.
"They provide incredible care for people when they're really vulnerable," she said.
"They're in the last stages of their life, and they support people who are dying, and also the families."
Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Hospice facing 'heartbreaking' funding shortfall
Unsellable items cost charity £45,000
Dove House Hospice
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Biocom California's 2025 Economic Impact Report Highlights Importance of the State's Life Science Industry -- One of the Top Industries in the Fourth Largest Economy in the World
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today released its 2025 Life Science Economic Impact Report, providing the most comprehensive report to date of the industry's economic footprint, innovation output and national leadership. 'California's life science industry remains a cornerstone of economic vitality and a global leader in health innovation." According to the report, the life science industry in California generated $396 billion in total business output, supported approximately 1.15 million jobs and played a central role in the development of at least 12 novel therapies approved by the U.S. Food and Drug Administration in 2024—more than any other state. 'California's life science industry remains a cornerstone of economic vitality and a global leader in health innovation,' said Tim Scott, president and CEO of Biocom California. 'Even amid economic tightening and political uncertainty, our sector continues to drive the discovery and delivery of life-changing treatments, medical devices and diagnostics around the world.' Scott continued: 'In a second consecutive year of economic headwinds, California's life science entrepreneurs remain a force of unstoppable resilience. They continue to advance bold science, build new ventures and deliver innovation that improves lives around the world. We are honored to champion their work at every stage. From policy advocacy and capital connections to workforce development, group purchasing, and strategic partnerships, our commitment to supporting our members has never been stronger.' This year's report features stories that highlight the medicines born in California and the scientific visionaries behind them. It is a tribute to the scientists, founders and teams across the state whose work delivers hope and health to patients worldwide. Key Findings from Biocom California's 2025 Life Science Economic Impact Report: California's life science industry generated $396 billion in total business output and directly employed more than 452,000 Californians in 2024, with a broader economic footprint supporting approximately 1.15 million jobs in the state. The state's life science ecosystem contributed directly to at least 12 of the 50 novel therapies approved by the U.S. F.D.A. in 2024 including medicines to treat cancer, rare diseases, mental health disorders, infectious diseases and more. The state leads the nation in biomanufacturing, providing over 141,000 direct life science manufacturing jobs, representing 31.2% of California's life science payroll employment. California research institutions received $5.7 billion in funding from the National Institutes of Health (NIH) and National Science Foundation (NSF) in 2024—the highest of any U.S. state. The state attracted $63.1 billion in private capital, including major venture and mergers and acquisitions (M&A) transactions, despite headwinds in the capital markets. Life-Saving Therapies Nurtured by Public and Private Investment California is the most productive hub for the development of innovative treatments of disease, many of which are supported by public investment. In 2024, California researchers received a total of $5.7 billion in federal funding from the NIH and NSF, more than any other U.S. state. These grants supported a range of health-related areas of research, including Alzheimer's disease and related dementias, stimulants, pain management, Lyme and tick-borne diseases, antimicrobial resistance, universal flu vaccine, mental health research and others. Also critical to the health of the life science industry is private investment in the form of venture capital and corporate M&A transactions. Total 2024 private sector investment in California came to $63.1 billion, which includes private equity and funding realized through the initial public offering process. Venture investment, typically raised by earlier stage companies, is important to establish early data showing the potential of new therapeutic approaches, which often originate in academia. M&A investment is frequently necessary to fully realize the potential of those new therapeutic approaches, as venture-funded companies frequently lack the resources to execute large, late-stage clinical studies and the corporate infrastructure necessary for commercialization of innovative technologies. California is the Biomanufacturing Leader Biocom California's Economic Impact Report found that 31.2% of life science payroll jobs in 2024 were in biomanufacturing, for a total of 141,000 jobs. Robust manufacturing capabilities are vital for global health impact, emergency preparedness, compliance with environmental and regulatory requirements. Such capabilities tend to have an out-sized impact on local economies due to labor-intensive processes, supply chain complexity and high-value raw material inputs. Importantly, biomanufacturing offers a pathway to living-wage careers, averaging $135,147 per year in California, for individuals with associate's degrees. In fact, 42% of life science degrees awarded in the state in 2024 were at the associate's level. 'The life science industry provides valuable jobs to Californians from a wide range of educational backgrounds,' said Scott. 'The prevalence of jobs specifically in manufacturing demonstrates a robust path into the life science industry for California residents from all economic backgrounds, and many community colleges are partnering with industry leaders to develop educational curricula to meet the needs of biomanufacturing companies.' California Brings Life-Saving Medicines to Patients In 2024, 50 unique novel drugs were approved by the U.S. FDA, and at least 12 of those came from California-headquartered companies addressing disease areas such as cancer, muscular dystrophy, heart disease and more. 'Patients from all over the world benefit from the innovation driven by the life science ecosystem in California, and citizens of the state benefit from the direct jobs and the overall economic impact,' concluded Mr. Scott. 'We invite the public as well as state and federal legislators and municipalities to learn more about the industry, its life-saving therapies and its economic impact. The California life science industry is a force behind the world's fourth largest economy and a source of pride for Californians.' To access the full report, visit About Biocom California Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom California, please visit our website at Connect with us on LinkedIn, Facebook and X.
Business Insider
4 days ago
- Business Insider
ProAssurance stockholders approve proposed acquisition by The Doctors Company
ProAssurance (PRA) Corporation announced that stockholders have voted overwhelmingly to approve its proposed acquisition by The Doctors Company. More than 99% of shares voted were in favor of the proposal to approve the acquisition agreement. The transaction remains subject to the receipt of regulatory approvals and other customary closing conditions and is expected to close in the first half of 2026. Required regulatory approvals include the expiration or early termination of the waiting period applicable to the consummation of the merger under the Hart-Scott-Rodino Act as well as approvals by the insurance regulators in the domicile states of ProAssurance insurance subsidiaries. The transaction is not subject to a financing condition. Upon completion of the transaction, ProAssurance's common stock will no longer be listed on the New York Stock Exchange, and ProAssurance will become a wholly owned subsidiary of The Doctors Company. 'Our shareholders recognize that this transaction will deliver significant value,' said Ned Rand, ProAssurance's President and Chief Executive Officer. He added, 'Bringing the strengths and capabilities of ProAssurance and The Doctors Company together will allow our teams to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities. With a shared history in the medical professional liability marketplace, both companies work to fulfill a mission to protect others and have similar operating philosophies and cultures.' Confident Investing Starts Here:
Entrepreneur
4 days ago
- Entrepreneur
How To Trust Your Instincts During a Pivot
Get lessons in leadership and decision-making from renowned health expert Dr. Drew Pinsky and serial investor Kim Perell on this episode of Entrepreneur Therapy. Roy Scott used to write raps that promoted violence and drug use. But seeing his young son repeating his lyrics changed everything. "That was just a light bulb," he says. "Like, I can't do this anymore." As the founder and CEO of Healthy Hip Hop, Scott is on a mission to bring clean, positive hip hop to kids and families. He has scaled the company through school partnerships, government contracts, and a new direct-to-consumer app. But with that growth has come pressure. Scott wants to scale the business but worries that he's not making the right decisions. "I just want to kind of mitigate that risk. I want to make more of the right decisions and [fewer] wrong decisions," he says. In this episode of Entrepreneur Therapy, presented by Amazon Business, Dr. Drew and Kim Perell help Scott tackle one of the toughest parts of entrepreneurship: trusting your instincts. Related: Know When to Trust Your Gut and When to Seek Outside Advice Scott explains that after finding early traction with schools and government contracts, changes in budget availability forced him to rethink his strategy and go direct to consumer. Perell reassures him that this is not a misstep, but part of the entrepreneurial journey. "99% of all the most successful entrepreneurs I've ever met have pivoted at least once," she says. "Having the courage to make a change is amazing." Regarding Scott's personal journey, Dr. Drew homes in on on his mindset around decision-making. He notices Scott switching between "we" and "I" when talking about the business and asks, "How does it feel to be in a leadership position — is that comfortable for you?" Scott says he feels confident as a leader but leans heavily on his team. Dr. Drew challenges him to step more fully into his role: "I'm wondering if maybe you need to sort of take the reins a little more proactively and trust your instincts a little more — because ultimately, it's you." Scott admits that part of the reason he hesitates to make quick decisions stems from not wanting to make the wrong call. He also confesses: "I am hard on myself… I want to be the best version of myself, so I definitely need to show myself some more grace." To help him deal with that pressure, Perrel offers one of her go-to strategies: The 70 percent rule. "I know it's hard to make decisions without complete information," she says, "but if you have 70 percent of the information, my rule of thumb is: go." It's a simple guideline — one that reminds Scott (and anyone watching) that waiting for perfection is often the greater risk. Related: How to Master Decision-Making in a World Full of Options Watch the episode to learn more about Ahuja's challenges and the advice Dr. Drew and Perrell give to build smarter while staying grounded at home. Entrepreneur Therapy is presented by Amazon Business. Smart business buying starts with Amazon Business. Learn more.
